Clinical Trial

A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a multi-center, Phase 2, open-label, single dose level study of PRL3-zumab monotherapy in patients with unresectable or metastatic solid tumor.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2020-06-29; most recent amendment 2026-04-17.
Status change: Recruiting → Active, Not Recruiting 2024-10-01
Status change: Not Yet Recruiting → Recruiting 2020-12-14
Trial Details
NCT Number NCT04452955
Lead Sponsor Intra-IMMUSG Pte Ltd
Collaborators: Parexel
Conditions Solid Tumor
Enrollment 51 participants
Start Date 2020-12-12
Primary Completion 2026-12-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2026-04-22